VEA
AEGR

Virtus ETF Advisers’s Aegerion Pharmaceuticals AEGR Stock Holding History

Virtus ETF Advisers’s Portfolio AEGR Stock Details AEGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-64,959
Closed -$656K – 168
2015
Q4 		$656K Buy
+64,959
New +$782K 1.8% 11

Other funds holding AEGR

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Virtus ETF Advisers's AEGR Position: Q1 2016 in Review

Virtus ETF Advisers sold out of Aegerion Pharmaceuticals (AEGR) in Q1 2016, closing a stake of 64,959 shares — an estimated $656K sold.

Virtus ETF Advisers first reported a position in AEGR in Q4 2015 and held it in 1 quarter. The position peaked at $656K in Q4 2015. 101 funds tracked by Wall St. Rank hold AEGR as of Q1 2016.

  • Virtus ETF Advisers reported no remaining Aegerion Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
  • Virtus ETF Advisers sold 64,959 Aegerion Pharmaceuticals shares in Q1 2016, an estimated $656K.
  • Virtus ETF Advisers first reported a position in Aegerion Pharmaceuticals in Q4 2015 and held it in 1 quarter.
  • Virtus ETF Advisers's Aegerion Pharmaceuticals position peaked at $656K in Q4 2015.
  • 101 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q1 2016.

Based on Virtus ETF Advisers's 13F filing for Q1 2016, filed 16 May 2016.